|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SCCPDH |
Gene summary for SCCPDH |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SCCPDH | Gene ID | 51097 |
| Gene name | saccharopine dehydrogenase (putative) | |
| Gene Alias | CGI-49 | |
| Cytomap | 1q44 | |
| Gene Type | protein-coding | GO ID | GO:0006629 | UniProtAcc | Q8NBX0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51097 | SCCPDH | GSM4909282 | Human | Breast | IDC | 2.85e-30 | 6.44e-01 | -0.0288 |
| 51097 | SCCPDH | GSM4909293 | Human | Breast | IDC | 1.44e-11 | 3.12e-01 | 0.1581 |
| 51097 | SCCPDH | GSM4909296 | Human | Breast | IDC | 1.47e-04 | -1.97e-01 | 0.1524 |
| 51097 | SCCPDH | GSM4909298 | Human | Breast | IDC | 3.88e-03 | 1.44e-01 | 0.1551 |
| 51097 | SCCPDH | GSM4909308 | Human | Breast | IDC | 7.72e-10 | 4.31e-01 | 0.158 |
| 51097 | SCCPDH | GSM4909311 | Human | Breast | IDC | 5.07e-08 | -1.40e-01 | 0.1534 |
| 51097 | SCCPDH | GSM4909312 | Human | Breast | IDC | 1.15e-02 | 1.33e-01 | 0.1552 |
| 51097 | SCCPDH | GSM4909315 | Human | Breast | IDC | 6.74e-04 | -2.69e-01 | 0.21 |
| 51097 | SCCPDH | GSM4909319 | Human | Breast | IDC | 4.99e-13 | -2.14e-01 | 0.1563 |
| 51097 | SCCPDH | brca2 | Human | Breast | Precancer | 1.61e-13 | 5.17e-01 | -0.024 |
| 51097 | SCCPDH | brca3 | Human | Breast | Precancer | 1.42e-06 | 2.55e-01 | -0.0263 |
| 51097 | SCCPDH | M2 | Human | Breast | IDC | 3.38e-02 | 4.64e-01 | 0.21 |
| 51097 | SCCPDH | NCCBC14 | Human | Breast | DCIS | 1.24e-06 | 3.63e-01 | 0.2021 |
| 51097 | SCCPDH | NCCBC5 | Human | Breast | DCIS | 6.01e-05 | -1.92e-01 | 0.2046 |
| 51097 | SCCPDH | P1 | Human | Breast | IDC | 9.84e-05 | -2.79e-02 | 0.1527 |
| 51097 | SCCPDH | DCIS2 | Human | Breast | DCIS | 2.03e-16 | -1.89e-01 | 0.0085 |
| 51097 | SCCPDH | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.47e-05 | 3.97e-01 | -0.0811 |
| 51097 | SCCPDH | HTA11_78_2000001011 | Human | Colorectum | AD | 4.33e-04 | 4.21e-01 | -0.1088 |
| 51097 | SCCPDH | HTA11_347_2000001011 | Human | Colorectum | AD | 6.57e-08 | 3.93e-01 | -0.1954 |
| 51097 | SCCPDH | HTA11_1391_2000001011 | Human | Colorectum | AD | 2.05e-02 | 3.01e-01 | -0.059 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00066433 | Esophagus | ESCC | membrane lipid metabolic process | 130/8552 | 203/18723 | 9.29e-08 | 1.54e-06 | 130 |
| GO:00464673 | Esophagus | ESCC | membrane lipid biosynthetic process | 91/8552 | 142/18723 | 7.19e-06 | 7.19e-05 | 91 |
| GO:00066642 | Esophagus | ESCC | glycolipid metabolic process | 63/8552 | 100/18723 | 3.55e-04 | 2.06e-03 | 63 |
| GO:19035092 | Esophagus | ESCC | liposaccharide metabolic process | 63/8552 | 101/18723 | 5.25e-04 | 2.90e-03 | 63 |
| GO:0009247 | Esophagus | ESCC | glycolipid biosynthetic process | 42/8552 | 68/18723 | 5.48e-03 | 2.05e-02 | 42 |
| GO:0006643 | Liver | Cirrhotic | membrane lipid metabolic process | 69/4634 | 203/18723 | 1.89e-03 | 1.19e-02 | 69 |
| GO:00066431 | Liver | HCC | membrane lipid metabolic process | 115/7958 | 203/18723 | 3.17e-05 | 3.22e-04 | 115 |
| GO:0046467 | Liver | HCC | membrane lipid biosynthetic process | 78/7958 | 142/18723 | 1.85e-03 | 9.46e-03 | 78 |
| GO:0006664 | Liver | HCC | glycolipid metabolic process | 57/7958 | 100/18723 | 2.40e-03 | 1.17e-02 | 57 |
| GO:1903509 | Liver | HCC | liposaccharide metabolic process | 57/7958 | 101/18723 | 3.25e-03 | 1.49e-02 | 57 |
| GO:00066432 | Oral cavity | OSCC | membrane lipid metabolic process | 111/7305 | 203/18723 | 4.02e-06 | 4.69e-05 | 111 |
| GO:00464672 | Oral cavity | OSCC | membrane lipid biosynthetic process | 77/7305 | 142/18723 | 1.63e-04 | 1.13e-03 | 77 |
| GO:00066641 | Oral cavity | OSCC | glycolipid metabolic process | 53/7305 | 100/18723 | 3.09e-03 | 1.33e-02 | 53 |
| GO:19035091 | Oral cavity | OSCC | liposaccharide metabolic process | 53/7305 | 101/18723 | 4.06e-03 | 1.66e-02 | 53 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SCCPDH | SNV | Missense_Mutation | c.1230N>T | p.Leu410Phe | p.L410F | Q8NBX0 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A8-A07B-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SCCPDH | SNV | Missense_Mutation | c.256G>C | p.Asp86His | p.D86H | Q8NBX0 | protein_coding | tolerated(0.12) | benign(0.213) | TCGA-BH-A18V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| SCCPDH | insertion | Nonsense_Mutation | novel | c.359_360insAGGAAGGGCTTCAGCTGATTTAAATTGGAAGTTCTT | p.Cys120delinsTer | p.C120delins* | Q8NBX0 | protein_coding | TCGA-A2-A04V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | PD | ||
| SCCPDH | SNV | Missense_Mutation | c.467C>A | p.Ser156Tyr | p.S156Y | Q8NBX0 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-EA-A439-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | |
| SCCPDH | SNV | Missense_Mutation | c.931N>C | p.Lys311Gln | p.K311Q | Q8NBX0 | protein_coding | tolerated(0.06) | benign(0.303) | TCGA-A6-6141-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | 5-fu | SD | |
| SCCPDH | SNV | Missense_Mutation | c.4G>A | p.Ala2Thr | p.A2T | Q8NBX0 | protein_coding | deleterious(0.04) | benign(0.017) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| SCCPDH | SNV | Missense_Mutation | novel | c.545N>T | p.Thr182Ile | p.T182I | Q8NBX0 | protein_coding | deleterious(0.02) | possibly_damaging(0.882) | TCGA-CM-5348-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
| SCCPDH | SNV | Missense_Mutation | c.1148N>C | p.Met383Thr | p.M383T | Q8NBX0 | protein_coding | tolerated(0.15) | benign(0.079) | TCGA-QG-A5Z2-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| SCCPDH | insertion | Nonsense_Mutation | novel | c.919_920insAAAGTTAG | p.Leu308SerfsTer2 | p.L308Sfs*2 | Q8NBX0 | protein_coding | TCGA-AM-5820-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| SCCPDH | insertion | Frame_Shift_Ins | novel | c.1184_1184+1insGGGCGGG | p.Val398GlyfsTer17 | p.V398Gfs*17 | Q8NBX0 | protein_coding | TCGA-G4-6299-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Ancillary | leucovorin | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |